Terry Dagnon
Net Worth

Last updated:

What is Terry Dagnon net worth?

The estimated net worth of Mr. Terry Dagnon is at least $3,018,845 as of 20 Apr 2023. He owns shares worth $1,756,726 as insider, has earned $623,399 from insider trading and has received compensation worth at least $638,720 in Outlook Therapeutics, Inc..

What is the salary of Terry Dagnon?

Mr. Terry Dagnon salary is $159,680 per year as Chief Operating Officer in Outlook Therapeutics, Inc..

How old is Terry Dagnon?

Mr. Terry Dagnon is 63 years old, born in 1962.

What stocks does Terry Dagnon currently own?

As insider, Mr. Terry Dagnon owns shares in one company:

Company Title Shares Price per share Total value
Outlook Therapeutics, Inc. (OTLK) Chief Operating Officer 653,058 $2.69 $1,756,726

What does Outlook Therapeutics, Inc. do?

Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

OTLK logo
OTLK
Outlook Therapeutics, Inc.
$2.69

Terry Dagnon insider trading

Outlook Therapeutics, Inc.

Mr. Terry Dagnon has made 3 insider trades between 2021-2023, according to the Form 4 filled with the SEC. Most recently he sold 520,000 units of OTLK stock worth $590,200 on 20 Apr 2023.

The largest trade he's ever made was exercising 520,000 units of OTLK stock on 20 Apr 2023. As of 20 Apr 2023 he still owns at least 653,058 units of OTLK stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 520,000 $1.14 $590,200
Purchase
Common Stock 10,000 $1.05 $10,500
Purchase
Common Stock 25,201 $1.38 $34,777
Purchase
Common Stock 10,000 $1.42 $14,200
Sale
Common Stock 15,900 $2.09 $33,199
Sale
Common Stock 63,700 N/A N/A

Outlook Therapeutics key executives

Outlook Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Mr. Jeffrey Evanson (56) Chief Commercial Officer
  • Mr. Lawrence A. Kenyon CPA (59) Chief Financial Officer, Treasurer, Company Sec. & Director
  • Mr. Terry Dagnon (63) Chief Operating Officer